Microalbuminuria is a recognized risk factor and predictor for cardiovascular events in patients with hypertension. We analyzed changes in hypotensive effect, urinary albumin excretion (UAE) and estimated glomerular filtration rate (eGFR) in subjects with hypertension and microalbuminuria as a subanalysis of the results of the Nifedipine and Candesartan Combination (NICE-Combi) Study. A total of 86 subjects with essential hypertension with microalbuminuria (UAE o300 mg g À1 creatinine) were randomly assigned in a double-blind manner to a combination therapy group (standard-dose candesartan at 8 mg per day plus controlledrelease (CR) nifedipine 20 mg per day) (n¼42) or an up-titrated monotherapy group (candesartan 12 mg per day) (n¼44) for 8 weeks of continuous treatment after initially receiving standard-dose candesartan (8 mg per day) monotherapy for 8 weeks (initial treatment). After 8weeks, blood pressure (BP) was significantly reduced in both groups compared with at the end of initial treatment. UAE also showed a significant decrease in the combination therapy group, while there was no significant change of eGFR in either group. A significant positive correlation was seen between BP reduction and UAE after 8 weeks of double-blind treatment in both groups, whereas no significant association was found between DUAE and DeGFR in either group. These findings show that combination therapy with standard-dose candesartan and nifedipine CR is more effective than up-titrated candesartan monotherapy for reducing BP and improving UAE while maintaining eGFR, and strongly suggest that the combination of an angiotensin II receptor blocker and long-acting calcium channel blocker is beneficial in patients with hypertension and microalbuminuria.
INTRODUCTION
The purpose of antihypertensive therapy for patients with chronic kidney disease (CKD) is to inhibit the development of renal dysfunction by decreasing blood pressure (BP) and preventing the onset or recurrence of cardiovascular disease. The renal-protective effects of renin-angiotensin system inhibitors have been demonstrated in many studies, [1] [2] [3] and clinical practice guidelines uniformly recommend an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II type 1 receptor blocker (ARB) as first-line treatment for CKD. [4] [5] [6] A calcium channel blocker (CCB) or diuretic is recommended as a second-line agent in combination with a renin-angiotensin system inhibitor. However, it still remains unclear which agent is more effective in slowing the progression of renal insufficiency in CKD patients in the context of changes in the glomerular filtration rate (GFR).
We previously reported that standard-dose combination therapy with an ARB plus controlled-release (CR) nifedipine is superior to uptitrated ARB treatment in lowering BP and reducing urinary albumin excretion (UAE) in the Nifedipine and Candesartan Combination (NICE-Combi) study. 7 In this study, which involves a subanalysis of the results of the NICE-Combi study, we used the Japanese equation proposed by the Japanese Society of Nephrology 8 to calculate estimated glomerular filtration rate (eGFR) and examine the association of DeGFR with DUAE to determine whether UAE reduction is associated with a decline in the eGFR.
METHODS

Study population
The methods of the NICE-Combi study were reported previously. 7 In this subanalysis, we included 86 subjects with microalbuminuria (UAE o300 mg g À1 creatinine) at the start of the study from the 258 subjects enrolled with essential hypertension. The reference value of microalbuminuria was X22 mg g À1 creatinine for men and X31 mg g À1 creatinine for women, according to the European Society of Hypertension-European Society of Cardiology (ESH/ESC) 2003 guideline. 9 Patients with overt nephropathy with a baseline UAE X300 mg g À1 creatinine were excluded from this study.
BP and renal function measurements
We estimated the GFR with a modified modification of diet in renal disease equation for Japanese: glomerular filtration rate (ml min À1 per 1.73 m 2 )¼ 194Â(serum creatinine) À1.094 Â(age) À0.287 (Â0.739 for females). 8 We examined changes in BP, UAE and eGFR measured on the designated appointment day (at trough before administration) again in the up-titrated monotherapy group (candesartan dosage increase to 12 mg per day) and the combination therapy group (candesartan 8 mg plus nifedipine CR 20 mg), to which patients had been randomly assigned using a double-blind design after initial treatment with candesartan (8 mg per day) monotherapy for 8 weeks. UAE and eGFR were measured before initial treatment, at the end of initial treatment and at the end of double-blind treatment, with UAE adjusted for urinary creatinine using the first urine in the morning. For blinding, we put tablets into opaque capsules to prevent the study drugs from being identified.
Statistical analysis
We compared the demographics of patients in the up-titrated monotherapy group and the combination therapy group by analysis of categorical variables, including gender and eGFR distribution, using the w 2 test and Fisher's exact test, and continuous variables, such as BP, UAE, serum creatinine and eGFR, using Student's t-test or the Wilcoxon rank-sum test. Changes in BP over 4 weeks and in UAE and eGFR for 8 weeks, in each group, were analyzed using a linear mixed model with Bonferroni correction. In addition, the interactions between changes in BP, UAE and eGFR in both groups were determined using the Type III test using a linear mixed model, and differences between groups at each time of measurement were evaluated using the Wilcoxon rank-sum test.
Values are expressed as the mean ± s.d., except for those of UAE and eGFR, which are given as median values (midpoint between 25th and 75th percentiles). We reviewed correlations between UAE and BP achieved at the end of doubleblind treatment in each treatment group using Spearman's rank correlation coefficient. We then calculated the coefficients of correlation and regression equations for the levels and DeGFR and DUAE during initial and double-blind treatment. If a normal distribution was not found, we used Spearman's rank correlation coefficient. Furthermore, we compared rates of progress and improvement with changes in UAE or eGFR as a category in the two groups using the w 2 test. All statistical analyses were two sided, with a level of significance of a-0.05, and performed with SAS software version 2010 (SAS Institute, Cary, NC, USA).
RESULTS
Subject demographics
The demographics of the 86 subjects (42 in the combination therapy group and 44 in the up-titrated monotherapy group) at the end of initial treatment are shown in Table 1 . No significant differences were seen between groups (mean eGFR 70.9 ± 23.2 ml min À1 per 1.73 m 2 in the combination therapy group and 64.6 ± 17.5 ml min À1 per 1.73 m 2 in the up-titrated monotherapy group; and mean UAE 81.0± 66.9 mg g À1 creatinine in the combination therapy group and 85.6 ± 69.5 mg g À1 creatinine in the up-titrated monotherapy group). In addition, no differences were seen between groups in BP or eGFR distribution by age.
Changes in BP
Changes of BP from initial treatment to the end of double-blind treatment in the two groups are shown in Figure 1 . Although no (eGFR X60) and eGFR o60 ml min À1 per 1.73 m 2 (eGFR o60), there were significant decreases of SBP and DBP after 4 weeks and at the end of double-blind treatment only in subjects from the combination therapy group with eGFR X60 but not in those with eGFR o60.
Changes in UAE
Changes of UAE from initial treatment to the end of double-blind treatment in the two groups are shown in Figure 2a . In all subjects, Combination therapy with ARB and long-acting CCB N Nakagawa et al a significant increase in UAE was observed after 8 weeks of initial treatment (Po0.01) (42 subjects in the combination therapy group: median from 40.1 to 56.7, P¼0.055; 44 in the up-titrated monotherapy group: median from 31.5 to 51.1, Po0.05). Although there was no significant decrease in UAE in the up-titrated monotherapy group during double-blind treatment, a significant decrease was seen in UAE in the combination therapy group (Po0.05), and the reduction at the end of the study was significant in comparison with the uptitrated monotherapy group (Po0.05). When we examined changes in UAE in patients stratified at an eGFR of 60 ml min À1 per 1.73 m 2 , the change was significantly lower in the combination therapy group (26.1 mg g À1 creatinine) than in the up-titrated monotherapy group (50.7 mg g À1 creatinine, Po0.05) at the end of double-blind treatment in subjects with eGFR X60 (Figure 2b ), but similar in the combination therapy group (40.5 mg g À1 creatinine) and the up-titrated monotherapy group (63.2 mg g À1 creatinine, P¼0.252) in subjects with eGFR o60 (Figure 2c ).
Changes in eGFR
Changes of eGFR from initial treatment to the end of double-blind treatment in the two groups are shown in Figure 2d . No significant changes were seen in both groups between baseline and the end of the study. Similar results were obtained in patients stratified by eGFR X60 and o60. In addition, examination of changes in eGFR according to subject age group revealed no significant difference between treatment groups for any stratum between before and after randomized treatment (Table 2) .
Relationships between BP, UAE and eGFR
Correlations between UAE and SBP at the end of double-blind treatment are shown in Figure 3 . Significant positive correlations were seen in both the combination therapy group (g¼0.453, Po0.01) and up-titrated monotherapy group (g¼0.334, Po0.05). There were only weak positive correlations (not significant) between DUAE and DSBP among subjects stratified by eGFR X60 and eGFR o60 from both the combination therapy group and the up-titrated monotherapy group. We then examined the correlations between DeGFR and DUAE before and after double-blind treatment. No significant correlation was seen between DUAE and DeGFR during double-blind treatment in either the combination therapy group (g¼À0.195, P¼0.217) or the up-titrated monotherapy group (g¼0.214, P¼0.164) (Figure 4 ). In the combination therapy group, 27 of 35 subjects (77%) with an increase of UAE during initial treatment showed a decrease of UAE during double-blind treatment, whereas 22 of 38 subjects (58%) with increased UAE during initial treatment showed a decrease during double-blind treatment in the up-titrated monotherapy group. Comparison between groups revealed a strong tendency to improvement in UAE in the combination therapy group (P¼0.080).
DISCUSSION
In this study, which involved a subanalysis of the results of the NICECombi study, we demonstrated the following: (1) BP level was significantly decreased in both groups with intensive antihypertensive Combination therapy with ARB and long-acting CCB N Nakagawa et al treatment, but BP reduction was significantly earlier and greater in the combination therapy group than in the up-titrated monotherapy group; (2) eGFR did not change significantly in either group, although UAE decreased significantly in the combination therapy group alone in parallel with BP reduction during 8 weeks of double-blind treatment. Recently, the GUARD study in the United States 10 showed treatment with an ACEI (benazepril) plus a diuretic (hydrochlorothiazide) in patients with diabetic nephropathy reduced albuminuria to a greater extent than an ACEI plus CCB (amlodipine). These results called into question whether a diuretic or CCB is more suitable as a second-line agent with a renin-angiotensin system inhibitor. However, treatment with ACEI plus CCB (À2.03 ml min À1 per year) was superior to ACEI plus diuretic (À13.64 ml min À1 per year) for maintenance of eGFR, apparently because reduction of UAE with the latter treatment was caused by a decline in eGFR. In general, eGFR can decrease temporarily in patients with CKD who are placed on a strict antihypertensive treatment regimen for a short period of time. However, in the analysis of renal events in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) study, 11, 12 combined treatment with ARB plus ACEI significantly reduced UAE in comparison with monotherapy with either agent alone, but eGFR reduction (À6.11 ml min À1 per year) and renal events were significantly greater, suggesting that renal events cannot be prevented by UAE reduction if there is an excessive decline of the eGFR. Therefore, the characteristics of antihypertensive therapy should be examined in relation to changes of the eGFR.
In the present study, we found that the BP reduction was greater in the combination therapy group than in the up-titrated monotherapy group, and that UAE declined significantly in the combination therapy group alone, while eGFR was unchanged over 8 weeks of intensive antihypertensive treatment and no significant correlation was found between DGFR and DUAE in either group. Furthermore, the percentage of subjects with improved UAE after double-blind treatment was higher in the combination therapy group than in the up-titrated monotherapy group, although the difference was not significant. When we examined changes of UAE in subjects stratified at an eGFR of 60 ml min À1 per 1.73 m 2 , marked improvement was seen in subjects from the combination therapy group with eGFR X60, suggesting that combination therapy with nifedipine CR reduces UAE without affecting the eGFR, so that the improvement of UAE may be attributed to increased tubular protein reabsorption. There was a weak positive correlation (not significant) between DUAE and DSBP in subjects with both eGFR X60 and eGFR o60 from both therapy groups, probably because the number of subjects in each stratified group was too small.
A meta-analysis found that a higher rate of achievement of an SBP o130 mm Hg, or a decrease in BP, in patients with CKD leads to decreased impairment in eGFR and prevention of end-stage renal disease. 13 As shown in Figure 3 , we found greater improvement of UAE in subjects who reached a lower BP in both the combination therapy group and the up-titrated monotherapy group, suggesting that UAE is worsen by standard dosage ARB treatment but can be improved by the intensive antihypertensive treatment. Basic studies have reported that nifedipine CR not only has stronger antihypertensive effects than other CCBs, but also strongly inhibits activation and secretion of aldosterone through a mineralocorticoid receptor, and that the strength of effect on aldosterone activation varies between CCB. 14 Previous studies have shown that nifedipine reduces levels of expression of monocyte chemoattractant protein-1, transforming growth factor-b, type III collagen and receptors for advanced glycation end products in advanced glycation end-exposed human cultured mesangial cells, 15 and may act as an anti-inflammatory and antifibrogenic agent against advanced glycation end via mineralocorticoid antagonistic activity. 16 These studies indicate that combination therapy with an ARB plus nifedipine CR may have strong BP-decreasing effects and organ-protective effects, and may thus improve renal function.
Recently, several studies comparing use of a CCB or diuretic with an renin-angiotensin system inhibitor have been published. Initially, in the Antihypertensive and Lipid Lowering treatment to prevent Heart ATtack (ALLHAT) 17 conducted in 30 000 patients with hypertension, amlodipine was found to be superior to ACEI and diuretics in delaying the decline in renal function and maintaining GFR in terms of the serum creatinine level (inverse per year), an indicator of renal function. Second, the International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT) study 18, 19 compared the effects on renal function in patients with high-risk hypertension between once-daily nifedipine formulations and combined co-amilozide (hydrochlorothiazide plus amiloride) groups, and reported that the former treatment significantly inhibited decline in GFR in comparison with the latter. Most recently, a subanalysis of renal outcome data in the Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) study 20 demonstrated a significantly slower decline in eGFR after 2.9 years of treatment in the benazepril (ACEI) plus amlodipine (CCB) group (À0.88 ml min À1 per 1.73 m 2 ) than in the benazepril plus hydrochlorothiazide (diuretic) group (À4.22 ml min À1 per 1.73 m 2 ; P¼0.01) in some 11 500 patients at high cardiovascular risk. It has also been reported that CCBs, especially those of the dihydropyridine class, increase urinary sodium and water excretion, partly by decreasing proximal tubular sodium reabsorption. 21, 22 In addition, CCBs have been proven to be effective in preventing arteriosclerosis, 23, 24 whereas diuretics can damage the sugar/fat metabolism system, 25,26 a possible factor in exacerbation of atherosclerosis.
This study has several limitations. One limitation of the NICECombi study is its lack of direct comparison with diuretics, as we did not include a treatment arm with ARB plus diuretic. The effects of combination treatment including ARB, long-acting CCBs and diuretics in patients with CKD require examination in large randomized studies. In addition, it has been reported in a clinical study that protective effects on organs may differ among CCBs, [27] [28] [29] and a controlled trial is needed to investigate antihypertensive effects and protection of organs in patients with CKD. Second, the up-titrated dose of candesartan was 12 mg per day, which is the maximum recommended dose in Japan, so the achieved SBP significantly differed by about 10 mm Hg between the two groups. There is still a possibility that other ARB monotherapy up-titrated to double the standard dose could reduce BP and UAE to the same extent as the combination therapy. Third, our subjects were all Japanese, and several studies have reported racial/ethnic differences in BP responses to antihypertensive therapy. 30 Finally, 8 weeks of double-blind treatment was a relatively short period to estimate long-term improvement of renal function. Further studies are needed to clarify these issues in large number of patients and long-term administration.
In conclusion, it appears that ARB plus nifedipine CR treatment can provide rapid and greater hypotensive effects and contribute to the preservation/improvement of renal function, in which UAE is reduced while maintaining eGFR. Our findings strongly suggest that early use of nifedipine CR is effective in patients with hypertension and microalbuminuria.
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